Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24804482 | 0.85 | ADRA2A (0.33) | WNT3ATNKS2MAPK1CCR1CCR5 | |
| SCHEMBL15339543 | 0.82 | CCR1 (0.34) | MAPK1CCR1CCR5CCR8NOS3 | |
| SCHEMBL1210409 | 0.78 | LIMK1 (0.30) | — | |
| SCHEMBL20614676 | 0.78 | — | — | |
| SCHEMBL30695898 | 0.78 | LIMK1 (0.30) | — | |
| SCHEMBL13336015 | 0.77 | PIK3CD (0.33) | WNT3ATNKS2PIK3CD | |
| SCHEMBL27099118 | 0.77 | MAP3K14 (0.37) | PIK3CDMAP3K14 | |
| SCHEMBL26835525 | 0.77 | MAP3K14 (0.32) | PIK3CDMAP3K14 | |
| SCHEMBL16265134 | 0.77 | PIK3CD (0.30) | PIK3CD | |
| SCHEMBL15316127 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-30 | — | — | US | disclosed |
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | US | disclosed |
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3478673-B1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-16 | — | — | EP | disclosed |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-25 | — | — | US | disclosed |
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-8772200-B2 | Nitrogen-containing heterocyclic compound and agricultural fungicide | NIPPON SODA CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-8772200-B2 | Nitrogen-containing heterocyclic compound and agricultural fungicide | NIPPON SODA CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| WO-2013059587-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | disclosed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | disclosed |
| US-20120289702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND AGRICULTURAL FUNGICIDE | NIPPON SODA CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120289702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND AGRICULTURAL FUNGICIDE | NIPPON SODA CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8163901-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-8163901-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-24 | — | — | US | disclosed |
| WO-2011019060-A1 | HEDGEHOG SIGNAL INHIBITOR | 協和発酵キリン株式会社 (JP) | 2011-02-17 | — | — | WO | disclosed |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2011-02-03 | — | — | US | disclosed |
| WO-2008025509-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | WNT3A 2895/4885TNKS2 3036/4885PIK3CD 1270/4885 |
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, NFKBIA, MAP3K15 | WNT3A 3968/4885TNKS2 348/4885PIK3CD 422/4885 |
| US-20120289702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND AGRICULTURAL FUNGICIDE | CBR3, CBR1, NOX3 | WNT3A 3138/4885TNKS2 4837/4885PIK3CD 2954/4885 |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | WNT3A 2895/4885TNKS2 3036/4885PIK3CD 1270/4885 |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | WNT3A 1993/4885TNKS2 547/4885PIK3CD 1599/4885 |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | WNT3A 4213/4885TNKS2 341/4885PIK3CD 382/4885 |
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | WNT3A 4677/4885TNKS2 4420/4885PIK3CD 2205/4885 |
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | WNT3A 3968/4885TNKS2 348/4885PIK3CD 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.